key: cord-0709805-xllj2pim
authors: Le, Brian L.; Andreoletti, Gaia; Oskotsky, Tomiko; Vallejo-Gracia, Albert; Rosales, Romel; Yu, Katharine; Kosti, Idit; Leon, Kristoffer E.; Bunis, Daniel G.; Li, Christine; Kumar, G. Renuka; White, Kris M.; García-Sastre, Adolfo; Ott, Melanie; Sirota, Marina
title: Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19
date: 2021-03-30
journal: Res Sq
DOI: 10.21203/rs.3.rs-333578/v1
sha: 9e85ac89f07725339d7e50384592c5ab04be2fc7
doc_id: 709805
cord_uid: xllj2pim

The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or generate lists of differentially expressed genes between control and SARS-CoV-2-infected samples. Using a rank-based pattern matching strategy based on the Kolmogorov-Smirnov Statistic, the signatures were queried against drug profiles from Connectivity Map (CMap). We validated sixteen of our top predicted hits in live SARS-CoV-2 antiviral assays in either Calu-3 or 293T-ACE2 cells. Validation experiments in human cell lines showed that 11 of the 16 compounds tested to date (including clofazimine, haloperidol and others) had measurable antiviral activity against SARS-CoV-2. These initial results are encouraging as we continue to work towards a further analysis of these predicted drugs as potential therapeutics for the treatment of COVID-19.

In this study, we applied our drug repositioning pipeline to SARS-CoV-2 differential 177 gene expression signatures derived from publicly available RNA-seq data ( Figure 1 ). The 178 transcriptomic data were generated from distinct types of tissues, so rather than 179 aggregating them together, we predicted therapeutics for each signature and then these signatures can be found in the supplement (Tables S1, S2, S3). After analyzing the input SARS-CoV-2 signatures, we utilized our repositioning 221 pipeline to identify drugs with reversed profiles from CMap ( Figure 1 ). Significantly 222 reversed drug profiles were identified for each of the signatures using a permutation 223 approach: 30 hits from the ALV signature (Table S4) , 15 hits from the EXP signature 224 (Table S5) , and 86 hits from the BALF signature (Table S6) (Table S7) . Twenty-five drug hits 232 reversed at least two signatures (p = 0.0334, random sampling), and four drug hits 233 reversed three signatures (p = 0.0599, random sampling) ( Table 1 , Figure 3A ). 234 We further characterized the common hits by examining their interactions with 235 proteins in humans. We used known drug targets from DrugBank 32 and predicted 236 additional targets using the similarity ensemble approach (SEA) 33 . We visualized the 237 known interactions from DrugBank in a network. Figure 3B shows the connectivity across 238 compounds highlighting both single drug genes (such as SIGMAR1 for haloperidol) and 239 genes shared across drugs, such as ADRA2A and DRD1 for haloperidol and co- can rapidly identify readily available potential therapeutics in antiviral contexts.

There are several limitations of our approach that should be recognized. In 

In our work, we applied the KS-based similarity metric on the CMap database. 

Study design 403 We have previously developed and used a transcriptomics based bioinformatics (Table S1) . 

We additionally applied a fold-change cutoff (|log2 FC| > 2), resulting in 125 genes used 425 as the EXP signature (Table S2) . (Table S3) . We generated lists of statistically significant differentially expressed genes from the analysis of 775 three published studies of SARS-CoV-2 and COVID-19. The drug repositioning computational 776 pipeline compares the ranked differential expression of the COVID-19 disease signature with that 777 of drug profiles from CMap. A reversal score based on the Kolmogorov-Smirnov statistic is 778 generated for each disease-drug pair. If a drug profile significantly (FDR < 0.05) reverses the 779 disease signature, then the drug could be therapeutic for the disease. Across all datasets, a total 780 of 102 drugs have been identified as potentially therapeutic for COVID-19. Twenty-five drugs were 781 identified in analyses of at least two of the three datasets. We further conducted pathways 782 analyses and targeted analyses on the results, focusing on the 25 shared hits. Finally, we 783 validated sixteen of our top predicted hits in live SARS-CoV-2 antiviral assays. 784 The lack of a dose response in cell viability probably reflects cytostatic and not cytotoxic effects. 820

Data are mean ± s.d.; n = 3 biologically independent samples for cell viability data. 821 

Predicted COVID-19 617 fatality rates based on age, sex, comorbidities and health system capacity

Extrapulmonary manifestations of COVID-19

Inborn errors of type I IFN immunity in patients with life-622 threatening COVID-19

COVID-19: 625 consider cytokine storm syndromes and immunosuppression. The Lancet

A protein interaction map identifies existing drugs targeting 628

Silico Discovery of Candidate Drugs against Covid-19

Remdesivir for the Treatment of Covid-19 -632

Commissioner O of the. FDA Approves First Treatment for COVID-19. FDA

Collaborative Group

Patients with Covid-19 -Preliminary Report

The price of innovation: new estimates of drug 640 development costs

Old drugs -new uses

A SARS-CoV-2 protein interaction map reveals 645 targets for drug repurposing

Network-based drug repurposing for 648 novel coronavirus 2019-nCoV/SARS-CoV-2

Comparative host-coronavirus protein interaction 651 networks reveal pan-viral disease mechanisms

In silico studies on therapeutic agents for COVID-19: Drug 654 repurposing approach

Discovery and Preclinical Validation of Drug Indications 656

Using Compendia of Public Gene Expression Data

Topiramate for Inflammatory Bowel Disease

Identification of alpha-adrenergic 662 agonists as potential therapeutic agents for dermatomyositis through drug-repurposing 663 using public expression datasets

Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells 667

In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling

Reversal of cancer gene expression correlates with drug 670 efficacy and reveals therapeutic targets

A Drug Repositioning Approach Identifies Tricyclic 673

Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine 674

Computational discovery of 676 therapeutic candidates for preventing preterm birth

Reversal of Infected Host Gene Expression Identifies 679

Repurposed Drug Candidates for COVID-19. bioRxiv

Imbalanced Host Response to SARS-682

CoV-2 Drives Development of COVID-19

SARS-CoV-2 Cell Entry Depends on 685 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 productively infects human gut 688 enterocytes

Transcriptomic characteristics of bronchoalveolar lavage fluid 690 and peripheral blood mononuclear cells in COVID-19 patients

The Connectivity Map: using gene-expression 693 signatures to connect small molecules, genes, and disease

Gene set enrichment analysis: A knowledge-696 based approach for interpreting genome-wide expression profiles

PGC-1α-responsive genes involved in 699 oxidative phosphorylation are coordinately downregulated in human diabetes

Single-cell landscape of bronchoalveolar immune cells in 702 patients with COVID-19

DrugBank 5.0: a major update to the DrugBank 704 database for 2018

Relating protein 707 pharmacology by ligand chemistry

Schizophrenia: more dopamine, more D2 receptors

Novel antiviral 715 activity of mung bean sprouts against respiratory syncytial virus and herpes simplex virus 716

−1: an in vitro study on virally infected Vero and MRC-5 cell lines

Antiviral activities of extremophilic 719 actinomycetes extracts from Kazakhstan's unique ecosystems against influenza viruses 720 and paramyxoviruses

Clofazimine: current 724 status and future prospects

Clofazimine is a broad-spectrum coronavirus inhibitor that 727 antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters

Systematic integration of biomedical knowledge 732 prioritizes drugs for repurposing. Valencia A

A Next Generation Connectivity Map: L1000 735 platform and the first 1,000,000 profiles

Entrez Gene: gene-centered information at NCBI

GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A 741 case series

Drug Repositioning: New Opportunities for Older

Silico Drug Design

A review of connectivity map and computational 748 approaches in pharmacogenomics

EMUDRA: Ensemble of Multiple Drug 751

Repositioning Approaches to improve prediction accuracy

Systematic evaluation of connectivity map for 754 disease indications

National Genomics Data Center Members and Partners. Database Resources of the 756

Molecular signatures database (MSigDB) 3.0

Database for Annotation, Visualization, 764 and Integrated Discovery

Normalization and variance stabilization of single-cell RNA-seq 766 data using regularized negative binomial regression

For each column, 789 the gene expression values were ranked, with rank 1 being the most up-regulated gene (in red) 790 and the maximum rank (109 for ALV) being the most down-regulated gene (in blue). Drug 791 names highlighted in green were hits for a second signature, and drug hits highlighted in purple 792 reversed all three signatures